CliffBio
small molecule

NEOPROFEN

IBUPROFEN LYSINE

Loss of exclusivityMarch 2032latest FDA-listed patent expiry
CompanyRecordati Rare Diseases Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameNEOPROFEN
Active ingredientIBUPROFEN LYSINE
StrengthEQ 20MG BASE/2ML (EQ 10MG BASE/ML)
Dosage formINJECTABLE
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalApril 2006
Marketing statusRX

Listed patents

PatentExpiresType
8415337March 2032substance, product

More from Recordati Rare Diseases Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.